Company intelligence / Profile preview

altona Diagnostics

Hamburg, Germanyaltona-diagnostics.com ↗

Ownership: Private
Employees: ~200
Development stage: Commercial

Overview

altona Diagnostics has over two decades of experience in molecular diagnostics. The company offers more than fifty CE-IVD marked real-time PCR kits for the detection of a wide range of pathogens. Their AltoStar® platform automates sample preparation to analysis. They have played key roles in providing rapid diagnostic solutions during outbreaks such as SARS, EHEC, MERS-CoV, Ebola virus and Zika virus. No clinical trial results as they are a diagnostics provider.

Therapeutic areas: Infectious Diseases
Modalities: Device (PCR-based diagnostic instruments)Diagnostic kit (Real-time PCR kits)Software (workflow automation for diagnostics)Nucleic acid extraction chemistry (for molecular diagnostics)
Industry: Molecular Diagnostics

Partnerships

Bernhard-Nocht-Institute for Tropical Medicine

Beyond the preview

Go deeper on altona Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on altona Diagnostics.

Explore the full profile